lactic acid has been researched along with HIV in 11 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " polylactic acid (PLA) for the treatment of facial lipoatrophy in HIV-infected adults." | 5.17 | Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. ( Bouchaud, O; Carbonnel, E; Dolivo, M; Girard, PM; Lafaurie, M; Loze, B; Madelaine, I; May, T; Molina, JM; Porcher, R, 2013) |
| "Perinatal antiretroviral (ARV) exposure has been related to hyperlactatemia and lactic acidosis in infants born to HIV-infected mothers." | 3.78 | Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue? ( Arranz, JA; Espiau, M; Figueras, C; Martín-Nalda, A; Martínez-Gómez, X; Melendo, S; Riudor, E; Soler-Palacín, P, 2012) |
| "Lactic acidosis in patients infected with the human immunodeficiency virus was initially identified as a rare complication of therapy with nucleoside analog reverse transcriptase inhibitors (NRTIs)." | 3.72 | Lactic acidemia in infection with human immunodeficiency virus. ( Carr, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hearps, AC | 1 |
| Tyssen, D | 1 |
| Srbinovski, D | 1 |
| Bayigga, L | 1 |
| Diaz, DJD | 1 |
| Aldunate, M | 1 |
| Cone, RA | 1 |
| Gugasyan, R | 1 |
| Anderson, DJ | 1 |
| Tachedjian, G | 1 |
| Lafaurie, M | 1 |
| Dolivo, M | 1 |
| Girard, PM | 1 |
| May, T | 1 |
| Bouchaud, O | 1 |
| Carbonnel, E | 1 |
| Madelaine, I | 1 |
| Loze, B | 1 |
| Porcher, R | 1 |
| Molina, JM | 1 |
| Lee, J | 2 |
| Tan, CY | 1 |
| Lee, SK | 2 |
| Kim, YH | 1 |
| Lee, KY | 2 |
| Soler-Palacín, P | 1 |
| Martín-Nalda, A | 1 |
| Martínez-Gómez, X | 1 |
| Melendo, S | 1 |
| Riudor, E | 1 |
| Arranz, JA | 1 |
| Espiau, M | 1 |
| Figueras, C | 1 |
| Choi, S | 1 |
| Kumar, P | 1 |
| Pattnaik, G | 1 |
| Sinha, B | 1 |
| Mukherjee, B | 1 |
| Ghosh, S | 1 |
| Basak, S | 1 |
| Mondal, S | 1 |
| Bera, T | 1 |
| Carr, A | 1 |
| Sharpe, S | 1 |
| Hanke, T | 1 |
| Tinsley-Bown, A | 1 |
| Dennis, M | 1 |
| Dowall, S | 1 |
| McMichael, A | 1 |
| Cranage, M | 1 |
| Haugaard, SB | 1 |
| Andersen, O | 1 |
| Dela, F | 1 |
| Holst, JJ | 1 |
| Storgaard, H | 1 |
| Fenger, M | 1 |
| Iversen, J | 1 |
| Madsbad, S | 1 |
| Treacy, PJ | 1 |
| Goldberg, DJ | 1 |
| Chen, CH | 1 |
| Cheng, YC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132[NCT00383734] | Phase 3 | 148 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)[NCT00119769] | Phase 4 | 46 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lactic acid and HIV
| Article | Year |
|---|---|
Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
Topics: Acrylic Resins; Adult; Aged; Anti-HIV Agents; Face; Female; HIV; HIV Infections; HIV-Associated Lipo | 2013 |
10 other studies available for lactic acid and HIV
| Article | Year |
|---|---|
Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition.
Topics: Anti-Inflammatory Agents; Cell Line; Cytokines; Epithelial Cells; Female; HIV; HIV Infections; Human | 2017 |
Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction.
Topics: Alginates; Apoptosis; Cell Hypoxia; Cell Line; Cell Proliferation; Cell Survival; Delayed-Action Pre | 2009 |
Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue?
Topics: Acidosis, Lactic; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cohort Studi | 2012 |
Single chain variable fragment CD7 antibody conjugated PLGA/HDAC inhibitor immuno-nanoparticles: developing human T cell-specific nano-technology for delivery of therapeutic drugs targeting latent HIV.
Topics: Anti-HIV Agents; Antigens, CD7; Cell Line; Chemistry, Pharmaceutical; Chromatography, High Pressure | 2011 |
Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; Delayed-Action Preparations; Didanosine; Drug Evaluation, | 2012 |
Lactic acidemia in infection with human immunodeficiency virus.
Topics: Acidosis, Lactic; HIV; HIV Infections; Humans; Lactic Acid; Outcome Assessment, Health Care; Reverse | 2003 |
Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
Topics: Administration, Rectal; AIDS Vaccines; Animals; Cytotoxicity Tests, Immunologic; Drug Carriers; Drug | 2003 |
Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.
Topics: Adult; Alanine; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Cholesterol, | 2005 |
Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs.
Topics: Adult; Aged; Anti-Retroviral Agents; Biopolymers; Cosmetic Techniques; Face; Female; Follow-Up Studi | 2006 |
Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cell Line; Cell Survival; Deoxyribonuclease BamHI; Dideoxynucleosides; DNA, Mitoch | 1989 |